ArticleNature communications2023

Neoadjuvant durvalumab plus radiation versus durvalumab alone in stages I-III non-small cell lung cancer: survival outcomes and molecular correlates of a randomized phase II trial.

Nasser K Altorki et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.